Condition
Seminoma clinical trials and research
As of November 12, 2026, Find a Trial lists 7 Seminoma clinical trials that are recruiting, at sites in 6 countries (most in Sweden (2), Germany (2), India (1)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 6Countries
Newest Seminoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer | — | Gothenburg, Göteborg | Recruiting | Mar 27, 2026 |
| De-escalation treatments for stage II seminoma | — | London | Recruiting | Mar 13, 2024 |
| Robot-assisted surgery for low-volume metastatic seminoma | Phase 2 | Düsseldorf | Recruiting | Nov 22, 2023 |
| Robot-assisted biopsy for testicular cancer | — | Düsseldorf | Recruiting | Nov 15, 2023 |
| De-escalation treatment for early-stage seminoma | Phase 2 | Besançon and 14 other locations | Recruiting | Sep 7, 2022 |
| Comparing radiotherapy and observation for residual seminoma after chemotherapy | — | Mumbai, Maharashtra and 1 other locations | Recruiting | Dec 3, 2021 |
| Using microRNA to improve testicular cancer management | — | Bergen and 5 other locations | Recruiting | Jun 4, 2021 |
All recruiting trials (7)
-
Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer
This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.
-
De-escalation treatments for stage II seminoma
This study is testing whether less intense treatments for stage II seminoma can help patients feel better and manage their cancer just as well as standard treatments.
-
Robot-assisted surgery for low-volume metastatic seminoma
This study is testing if robot-assisted surgery can help patients with low-volume metastatic seminoma avoid long-term side effects and improve their quality of life while also figuring out how to personalize their treatment.
-
Robot-assisted biopsy for testicular cancer
This study is testing a new robot-assisted method for taking biopsies in men with testicular cancer to see if it can more accurately find hidden cancer and reduce unnecessary treatments.
-
De-escalation treatment for early-stage seminoma
This study is testing whether giving less treatment after surgery for early-stage seminoma can still be effective while reducing side effects for patients.
-
Comparing radiotherapy and observation for residual seminoma after chemotherapy
This study is testing whether giving radiotherapy or just watching closely is better for patients with advanced seminoma who still have leftover masses after chemotherapy.
-
Using microRNA to improve testicular cancer management
This study is testing if a specific microRNA can help doctors better detect and manage testicular cancer by identifying active tumor cells in patients.
Related topics
Quick answers
How many Seminoma clinical trials are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in Sweden (2 trials), Germany (2 trials), India (1 trial), United Kingdom (1 trial), Norway (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.